82_FR_12268 82 FR 12229 - Blood Products Advisory Committee; Notice of Meeting

82 FR 12229 - Blood Products Advisory Committee; Notice of Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Federal Register Volume 82, Issue 39 (March 1, 2017)

Page Range12229-12230
FR Document2017-03944

The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Blood Products Advisory Committee. The general function of the committee is to provide advice and recommendations to the Agency on FDA's regulatory issues. At least one portion of the meeting will be closed to the public.

Federal Register, Volume 82 Issue 39 (Wednesday, March 1, 2017)
[Federal Register Volume 82, Number 39 (Wednesday, March 1, 2017)]
[Notices]
[Pages 12229-12230]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-03944]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-N-0001]


Blood Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming 
public advisory committee meeting of the Blood Products Advisory 
Committee. The general function of the committee is to provide advice 
and recommendations to the Agency on FDA's regulatory issues. At least 
one portion of the meeting will be closed to the public.

DATES: The meeting will be held on April 4, 2017, from 8:30 a.m. to 
3:45 p.m. and on April 5, 2017, from 8:30 a.m. to 12 p.m.

ADDRESSES: The meeting will be held at Tommy Douglas Conference Center, 
10000 New Hampshire Ave., Silver Spring, MD 20903. The conference 
center's telephone number is 240-645-4000. Answers to commonly asked 
questions including information regarding special accommodations due to 
a disability, visitor parking, and transportation may be accessed at: 
http://www.tommydouglascenter.com.

FOR FURTHER INFORMATION CONTACT: Bryan Emery or Joanne Lipkind, Center 
for Biologics Evaluation and Research, Food and Drug Administration, 
10903 New Hampshire Ave., Bldg. 71, Rm. 6132, Silver Spring, MD 20993-
0002, 240-402-8054, 240-402-8106, bryan.emery@fda.hhs.gov, 
joanne.lipkind@fda.hhs.gov; or FDA Advisory Committee Information Line, 
1-800-741-8138 (301-443-0572 in the Washington, DC area). A notice in 
the Federal Register about last minute modifications that impact a 
previously announced advisory committee meeting cannot always be 
published quickly enough to provide timely notice. Therefore, you 
should always check the Agency's Web site at http://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate 
advisory committee meeting link, or call the advisory committee 
information line to learn about possible modifications before coming to 
the meeting. For those unable to attend in person, the meeting will 
also be available via Webcast. The Webcast will be available at the 
following link for both days: April 4, 2017, 115th Meeting of the Blood 
Products Advisory Committee--Day 1 at: http://fda.yorkcast.com/webcast/Play/bb044b891a7b48ff82cc30b18ece526e1d; April 5, 2017, 115th Meeting 
of the Blood Products Advisory Committee--Day 2 at: http://fda.yorkcast.com/webcast/Play/b4068ead1c874966860584b421dcfd231d.

SUPPLEMENTARY INFORMATION:
    Agenda: On April 4, 2017, in open session, the Committee will 
discuss Recombinant Human Coagulation Factor IX, GlycoPEGylated. In the 
afternoon, in open session, the Committee will hear an update 
presentation on a summary of responses to Docket FDA-2016-N-1502: Blood 
Donor Deferral Policy for Reducing the Risk of Human Immunodeficiency 
Virus Transmission by Blood and Blood Products.
    On April 5, 2017, in open session, the committee will hear overview 
presentations on the research programs in the Laboratory of Emerging 
Pathogens in the Division of Emerging Transfusion-Transmitted Diseases, 
Office of Blood Research and Review, Center for Biologics Evaluation 
and Research, FDA. At the conclusion of the open session, the meeting 
will be closed to permit discussion where disclosure would constitute 
an unwarranted invasion of personal privacy in accordance with 5 U.S.C 
552b(c)(6). During the closed session, the Committee will discuss the 
research progress made by staff involved in the intramural research 
programs and make recommendations regarding their personnel actions and 
staffing decisions.
    FDA intends to make background material available to the public no 
later than 2 business days before the meeting. If FDA is unable to post 
the background material on its Web site prior to the meeting, the 
background material will be made publicly available at the location of 
the advisory committee meeting, and the background material will be 
posted on FDA's Web site after the meeting. Background material is 
available at: http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting 
link.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person on or before 
March 28, 2017. Oral presentations from the public will be scheduled 
between approximately 10:50 a.m. to 11:20 a.m. and will be scheduled 
between approximately 3:15 p.m. to 3:45 p.m. on April 4, 2017. Oral 
presentations from the public will be scheduled between approximately 
10:15 a.m. and 11:15 a.m. on April 5, 2017. Those individuals 
interested in making formal oral presentations should notify the 
contact person and submit a brief statement of the general nature of 
the evidence or arguments they wish to present, the names and addresses 
of proposed participants, and an indication of the approximate time 
requested to make their presentation on or before March 20, 2017. Time 
allotted for each presentation may be limited. If the number of 
registrants requesting to speak is greater than can be reasonably 
accommodated during the scheduled open public hearing session, FDA may 
conduct a lottery to determine the

[[Page 12230]]

speakers for the scheduled open public hearing session. The contact 
person will notify interested persons regarding their request to speak 
by March 21, 2017.
    Closed Committee Deliberations: On April 5, 2017, from 11:15 a.m. 
to 12:00 p.m., the meeting will be closed to permit discussion where 
disclosure would constitute a clearly unwarranted invasion of personal 
privacy (5 U.S.C. 552b(c)(6)). The Committee will discuss the report of 
the intramural research program and make recommendations regarding 
personnel staffing decisions.
    Persons attending FDA's advisory committee meetings are advised 
that the Agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
disabilities. If you require accommodations due to a disability, please 
contact Bryan Emery at least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee 
meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures 
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: February 24, 2017.
Janice M. Soreth,
Associate Commissioner for Special Medical Programs.
[FR Doc. 2017-03944 Filed 2-28-17; 8:45 am]
BILLING CODE 4164-01-P



                                                                                 Federal Register / Vol. 82, No. 39 / Wednesday, March 1, 2017 / Notices                                           12229

                                                    (301) 427–1111; TTY (toll free): (866)                  committee is to provide advice and                    Reducing the Risk of Human
                                                    438–7231; TTY (local): (301) 427–1130;                  recommendations to the Agency on                      Immunodeficiency Virus Transmission
                                                    Email: pso@ahrq.hhs.gov.                                FDA’s regulatory issues. At least one                 by Blood and Blood Products.
                                                    SUPPLEMENTARY INFORMATION:                              portion of the meeting will be closed to                 On April 5, 2017, in open session, the
                                                                                                            the public.                                           committee will hear overview
                                                    Background                                              DATES: The meeting will be held on                    presentations on the research programs
                                                       The Patient Safety Act authorizes the                April 4, 2017, from 8:30 a.m. to 3:45                 in the Laboratory of Emerging Pathogens
                                                    listing of PSOs, which are entities or                  p.m. and on April 5, 2017, from 8:30                  in the Division of Emerging
                                                    component organizations whose                           a.m. to 12 p.m.                                       Transfusion-Transmitted Diseases,
                                                    mission and primary activity are to                     ADDRESSES: The meeting will be held at                Office of Blood Research and Review,
                                                    conduct activities to improve patient                   Tommy Douglas Conference Center,                      Center for Biologics Evaluation and
                                                    safety and the quality of health care                   10000 New Hampshire Ave., Silver                      Research, FDA. At the conclusion of the
                                                    delivery.                                               Spring, MD 20903. The conference                      open session, the meeting will be closed
                                                       HHS issued the Patient Safety Rule to                center’s telephone number is 240–645–                 to permit discussion where disclosure
                                                    implement the Patient Safety Act.                       4000. Answers to commonly asked                       would constitute an unwarranted
                                                    AHRQ administers the provisions of the                  questions including information                       invasion of personal privacy in
                                                    Patient Safety Act and Patient Safety                   regarding special accommodations due                  accordance with 5 U.S.C 552b(c)(6).
                                                    Rule relating to the listing and operation              to a disability, visitor parking, and                 During the closed session, the
                                                    of PSOs. The Patient Safety Rule                        transportation may be accessed at:                    Committee will discuss the research
                                                    authorizes AHRQ to list as a PSO an                     http://www.tommydouglascenter.com.                    progress made by staff involved in the
                                                    entity that attests that it meets the                                                                         intramural research programs and make
                                                                                                            FOR FURTHER INFORMATION CONTACT:
                                                    statutory and regulatory requirements                                                                         recommendations regarding their
                                                                                                            Bryan Emery or Joanne Lipkind, Center
                                                    for listing. A PSO can be ‘‘delisted’’ if                                                                     personnel actions and staffing decisions.
                                                                                                            for Biologics Evaluation and Research,
                                                    it is found to no longer meet the                                                                                FDA intends to make background
                                                                                                            Food and Drug Administration, 10903
                                                    requirements of the Patient Safety Act                                                                        material available to the public no later
                                                                                                            New Hampshire Ave., Bldg. 71, Rm.
                                                    and Patient Safety Rule, when a PSO                                                                           than 2 business days before the meeting.
                                                                                                            6132, Silver Spring, MD 20993–0002,
                                                    chooses to voluntarily relinquish its                                                                         If FDA is unable to post the background
                                                                                                            240–402–8054, 240–402–8106,
                                                                                                                                                                  material on its Web site prior to the
                                                    status as a PSO for any reason, or when                 bryan.emery@fda.hhs.gov,
                                                                                                                                                                  meeting, the background material will
                                                    a PSO’s listing expires. Section 3.108(d)               joanne.lipkind@fda.hhs.gov; or FDA
                                                                                                                                                                  be made publicly available at the
                                                    of the Patient Safety Rule requires                     Advisory Committee Information Line,
                                                                                                                                                                  location of the advisory committee
                                                    AHRQ to provide public notice when it                   1–800–741–8138 (301–443–0572 in the
                                                                                                                                                                  meeting, and the background material
                                                    removes an organization from the list of                Washington, DC area). A notice in the
                                                                                                                                                                  will be posted on FDA’s Web site after
                                                    federally approved PSOs.                                Federal Register about last minute
                                                                                                                                                                  the meeting. Background material is
                                                       The Surgical Momentum PSO, PSO                       modifications that impact a previously
                                                                                                                                                                  available at: http://www.fda.gov/
                                                    number P0154, a component entity of                     announced advisory committee meeting
                                                                                                                                                                  AdvisoryCommittees/Calendar/
                                                    the Surgical Momentum, LLC, chose to                    cannot always be published quickly
                                                                                                                                                                  default.htm. Scroll down to the
                                                    let its listing expire by not seeking                   enough to provide timely notice.
                                                                                                                                                                  appropriate advisory committee meeting
                                                    continued listing. Accordingly, the                     Therefore, you should always check the
                                                                                                                                                                  link.
                                                    Surgical Momentum PSO was delisted                      Agency’s Web site at http://                             Procedure: Interested persons may
                                                    effective at 12:00 Midnight ET (2400) on                www.fda.gov/AdvisoryCommittees/                       present data, information, or views,
                                                    January 21, 2017.                                       default.htm and scroll down to the                    orally or in writing, on issues pending
                                                       More information on PSOs can be                      appropriate advisory committee meeting                before the committee. Written
                                                    obtained through AHRQ’s PSO Web site                    link, or call the advisory committee                  submissions may be made to the contact
                                                    at http://www.pso.ahrq.gov.                             information line to learn about possible              person on or before March 28, 2017.
                                                                                                            modifications before coming to the                    Oral presentations from the public will
                                                    Sharon B. Arnold,
                                                                                                            meeting. For those unable to attend in                be scheduled between approximately
                                                    Acting Director.                                        person, the meeting will also be
                                                    [FR Doc. 2017–03999 Filed 2–28–17; 8:45 am]
                                                                                                                                                                  10:50 a.m. to 11:20 a.m. and will be
                                                                                                            available via Webcast. The Webcast will               scheduled between approximately 3:15
                                                    BILLING CODE 4160–90–P                                  be available at the following link for                p.m. to 3:45 p.m. on April 4, 2017. Oral
                                                                                                            both days: April 4, 2017, 115th Meeting               presentations from the public will be
                                                                                                            of the Blood Products Advisory                        scheduled between approximately 10:15
                                                    DEPARTMENT OF HEALTH AND                                Committee—Day 1 at: http://
                                                    HUMAN SERVICES                                                                                                a.m. and 11:15 a.m. on April 5, 2017.
                                                                                                            fda.yorkcast.com/webcast/Play/                        Those individuals interested in making
                                                                                                            bb044b891a7b48ff82cc30b18ece526e1d;                   formal oral presentations should notify
                                                    Food and Drug Administration
                                                                                                            April 5, 2017, 115th Meeting of the                   the contact person and submit a brief
                                                    [Docket No. FDA–2017–N–0001]                            Blood Products Advisory Committee—                    statement of the general nature of the
                                                                                                            Day 2 at: http://fda.yorkcast.com/                    evidence or arguments they wish to
                                                    Blood Products Advisory Committee;                      webcast/Play/b4068ead1c874966860584                   present, the names and addresses of
                                                    Notice of Meeting                                       b421dcfd231d.                                         proposed participants, and an
                                                                                                                                                                  indication of the approximate time
asabaliauskas on DSK3SPTVN1PROD with NOTICES




                                                    AGENCY:    Food and Drug Administration,                SUPPLEMENTARY INFORMATION:
                                                    HHS.                                                       Agenda: On April 4, 2017, in open                  requested to make their presentation on
                                                    ACTION:   Notice.                                       session, the Committee will discuss                   or before March 20, 2017. Time allotted
                                                                                                            Recombinant Human Coagulation Factor                  for each presentation may be limited. If
                                                    SUMMARY:  The Food and Drug                             IX, GlycoPEGylated. In the afternoon, in              the number of registrants requesting to
                                                    Administration (FDA) announces a                        open session, the Committee will hear                 speak is greater than can be reasonably
                                                    forthcoming public advisory committee                   an update presentation on a summary of                accommodated during the scheduled
                                                    meeting of the Blood Products Advisory                  responses to Docket FDA–2016–N–1502:                  open public hearing session, FDA may
                                                    Committee. The general function of the                  Blood Donor Deferral Policy for                       conduct a lottery to determine the


                                               VerDate Sep<11>2014   18:09 Feb 28, 2017   Jkt 241001   PO 00000   Frm 00040   Fmt 4703   Sfmt 4703   E:\FR\FM\01MRN1.SGM   01MRN1


                                                    12230                        Federal Register / Vol. 82, No. 39 / Wednesday, March 1, 2017 / Notices

                                                    speakers for the scheduled open public                  would constitute a clearly unwarranted                SUMMARY:    The Department of Health and
                                                    hearing session. The contact person will                invasion of personal privacy.                         Human Services (HHS) notifies federal
                                                    notify interested persons regarding their                 Name of Committee: Center for Scientific            agencies of the laboratories and
                                                    request to speak by March 21, 2017.                     Review Special Emphasis Panel; Biomedical             Instrumented Initial Testing Facilities
                                                       Closed Committee Deliberations: On                   Engineering.                                          (IITF) currently certified to meet the
                                                    April 5, 2017, from 11:15 a.m. to 12:00                   Date: March 2–3, 2017.                              standards of the Mandatory Guidelines
                                                    p.m., the meeting will be closed to                       Time: 8:00 a.m. to 9:00 p.m.                        for Federal Workplace Drug Testing
                                                    permit discussion where disclosure                        Agenda: To review and evaluate grant                Programs (Mandatory Guidelines).
                                                                                                            applications.
                                                    would constitute a clearly unwarranted                    Place: National Institutes of Health, 6701
                                                                                                                                                                     A notice listing all currently HHS-
                                                    invasion of personal privacy (5 U.S.C.                  Rockledge Drive, Bethesda, MD 20892                   certified laboratories and IITFs is
                                                    552b(c)(6)). The Committee will discuss                 (Virtual Meeting).                                    published in the Federal Register
                                                    the report of the intramural research                     Contact Person: Joseph D Mosca, Ph.D.,              during the first week of each month. If
                                                    program and make recommendations                        Scientific Review Officer, Center for                 any laboratory or IITF certification is
                                                    regarding personnel staffing decisions.                 Scientific Review, National Institutes of             suspended or revoked, the laboratory or
                                                       Persons attending FDA’s advisory                     Health, 6701 Rockledge Drive, Room 5158,              IITF will be omitted from subsequent
                                                                                                            MSC 7808, Bethesda, MD 20892, (301) 435–              lists until such time as it is restored to
                                                    committee meetings are advised that the
                                                                                                            2344, moscajos@csr.nih.gov.
                                                    Agency is not responsible for providing                                                                       full certification under the Mandatory
                                                                                                              This notice is being published less than 15         Guidelines.
                                                    access to electrical outlets.                           days prior to the meeting due to the timing
                                                       FDA welcomes the attendance of the                   limitations imposed by the review and                    If any laboratory or IITF has
                                                    public at its advisory committee                        funding cycle.                                        withdrawn from the HHS National
                                                    meetings and will make every effort to                    Name of Committee: Center for Scientific            Laboratory Certification Program (NLCP)
                                                    accommodate persons with disabilities.                  Review Special Emphasis Panel; Member                 during the past month, it will be listed
                                                    If you require accommodations due to a                  Conflict: Health Services Organization and            at the end and will be omitted from the
                                                    disability, please contact Bryan Emery                  Delivery.                                             monthly listing thereafter.
                                                    at least 7 days in advance of the                         Date: March 6, 2017.                                   This notice is also available on the
                                                    meeting.                                                  Time: 8:00 a.m. to 5:00 p.m.                        Internet at http://www.samhsa.gov/
                                                                                                              Agenda: To review and evaluate grant
                                                       FDA is committed to the orderly                      applications.
                                                                                                                                                                  workplace.
                                                    conduct of its advisory committee                         Place: National Institutes of Health, 6701          FOR FURTHER INFORMATION CONTACT:
                                                    meetings. Please visit our Web site at                  Rockledge Drive, Bethesda, MD 20892                   Giselle Hersh, Division of Workplace
                                                    http://www.fda.gov/Advisory                             (Telephone Conference Call).                          Programs, SAMHSA/CSAP, 5600
                                                    Committees/AboutAdvisoryCommittees/                       Contact Person: Gabriel B Fosu, Ph.D.,
                                                                                                                                                                  Fishers Lane, Room 16N03A, Rockville,
                                                    ucm111462.htm for procedures on                         Scientific Review Officer, Center for
                                                                                                            Scientific Review, National Institutes of             Maryland 20857; 240–276–2600 (voice).
                                                    public conduct during advisory
                                                    committee meetings.                                     Health, 6701 Rockledge Drive, Room 3108,              SUPPLEMENTARY INFORMATION: The
                                                                                                            MSC 7808, Bethesda, MD 20892, (301) 435–              Department of Health and Human
                                                       Notice of this meeting is given under                3562, fosug@csr.nih.gov.
                                                    the Federal Advisory Committee Act (5                                                                         Services (HHS) notifies federal agencies
                                                                                                              This notice is being published less than 15         of the laboratories and Instrumented
                                                    U.S.C. app. 2).                                         days prior to the meeting due to the timing           Initial Testing Facilities (IITF) currently
                                                      Dated: February 24, 2017.                             limitations imposed by the review and
                                                                                                            funding cycle.
                                                                                                                                                                  certified to meet the standards of the
                                                    Janice M. Soreth,                                                                                             Mandatory Guidelines for Federal
                                                    Associate Commissioner for Special Medical              (Catalogue of Federal Domestic Assistance
                                                                                                            Program Nos. 93.306, Comparative Medicine;
                                                                                                                                                                  Workplace Drug Testing Programs
                                                    Programs.                                                                                                     (Mandatory Guidelines). The Mandatory
                                                                                                            93.333, Clinical Research, 93.306, 93.333,
                                                    [FR Doc. 2017–03944 Filed 2–28–17; 8:45 am]             93.337, 93.393–93.396, 93.837–93.844,                 Guidelines were first published in the
                                                    BILLING CODE 4164–01–P                                  93.846–93.878, 93.892, 93.893, National               Federal Register on April 11, 1988 (53
                                                                                                            Institutes of Health, HHS)                            FR 11970), and subsequently revised in
                                                                                                              Dated: February 23, 2017.                           the Federal Register on June 9, 1994 (59
                                                    DEPARTMENT OF HEALTH AND                                                                                      FR 29908); September 30, 1997 (62 FR
                                                                                                            Michelle Trout,
                                                    HUMAN SERVICES                                                                                                51118); April 13, 2004 (69 FR 19644);
                                                                                                            Program Analyst, Office of Federal Advisory
                                                                                                            Committee Policy.                                     November 25, 2008 (73 FR 71858);
                                                    National Institutes of Health                                                                                 December 10, 2008 (73 FR 75122); and
                                                                                                            [FR Doc. 2017–03903 Filed 2–28–17; 8:45 am]
                                                    Center for Scientific Review; Notice of                                                                       on April 30, 2010 (75 FR 22809).
                                                                                                            BILLING CODE 4140–01–P
                                                    Closed Meetings                                                                                                 The Mandatory Guidelines were
                                                                                                                                                                  initially developed in accordance with
                                                      Pursuant to section 10(d) of the                      DEPARTMENT OF HEALTH AND                              Executive Order 12564 and section 503
                                                    Federal Advisory Committee Act, as                      HUMAN SERVICES                                        of Public Law 100–71. The ‘‘Mandatory
                                                    amended (5 U.S.C. App.), notice is                                                                            Guidelines for Federal Workplace Drug
                                                    hereby given of the following meetings.                 Substance Abuse and Mental Health                     Testing Programs,’’ as amended in the
                                                      The meetings will be closed to the                    Services Administration                               revisions listed above, requires strict
                                                    public in accordance with the                                                                                 standards that laboratories and IITFs
                                                    provisions set forth in sections                        Current List of HHS-Certified                         must meet in order to conduct drug and
asabaliauskas on DSK3SPTVN1PROD with NOTICES




                                                    552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,              Laboratories and Instrumented Initial                 specimen validity tests on urine
                                                    as amended. The grant applications and                  Testing Facilities Which Meet Minimum                 specimens for federal agencies.
                                                    the discussions could disclose                          Standards To Engage in Urine Drug                       To become certified, an applicant
                                                    confidential trade secrets or commercial                Testing for Federal Agencies                          laboratory or IITF must undergo three
                                                    property such as patentable material,                   AGENCY: Substance Abuse and Mental                    rounds of performance testing plus an
                                                    and personal information concerning                     Health Services Administration, HHS.                  on-site inspection. To maintain that
                                                    individuals associated with the grant                                                                         certification, a laboratory or IITF must
                                                                                                            ACTION: Notice.
                                                    applications, the disclosure of which                                                                         participate in a quarterly performance


                                               VerDate Sep<11>2014   18:09 Feb 28, 2017   Jkt 241001   PO 00000   Frm 00041   Fmt 4703   Sfmt 4703   E:\FR\FM\01MRN1.SGM   01MRN1



Document Created: 2017-03-01 03:39:20
Document Modified: 2017-03-01 03:39:20
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
DatesThe meeting will be held on April 4, 2017, from 8:30 a.m. to 3:45 p.m. and on April 5, 2017, from 8:30 a.m. to 12 p.m.
ContactBryan Emery or Joanne Lipkind, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 6132, Silver Spring, MD 20993- 0002, 240-402-8054, 240-402-8106, [email protected], [email protected]; or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency's Web site at http://www.fda.gov/ AdvisoryCommittees/default.htm and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting. For those unable to attend in person, the meeting will also be available via Webcast. The Webcast will be available at the following link for both days: April 4, 2017, 115th Meeting of the Blood Products Advisory Committee--Day 1 at: http://fda.yorkcast.com/webcast/ Play/bb044b891a7b48ff82cc30b18ece526e1d; April 5, 2017, 115th Meeting of the Blood Products Advisory Committee--Day 2 at: http:// fda.yorkcast.com/webcast/Play/b4068ead1c874966860584b421dcfd231d.
FR Citation82 FR 12229 

2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR